Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
Status:
Completed
Trial end date:
2017-02-17
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine
after standard chemotherapy for patients with early triple negative breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Spanish Breast Cancer Research Group
Collaborators:
Hoffmann-La Roche IBEROAMERICAN COALITION FOR BREAST ONCOLOGY RESEARCH (CIBOMA)